 Biotransformation
"Biotransformation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
| Descriptor ID |
D001711
|
| MeSH Number(s) |
G03.171 G03.787.225 G07.690.725.225
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Biotransformation".
Below are MeSH descriptors whose meaning is more specific than "Biotransformation".
This graph shows the total number of publications written about "Biotransformation" by people in this website by year, and whether "Biotransformation" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 1 | 1 | | 1990 | 0 | 4 | 4 | | 1991 | 0 | 1 | 1 | | 1992 | 0 | 3 | 3 | | 1993 | 0 | 1 | 1 | | 1994 | 0 | 5 | 5 | | 1995 | 0 | 3 | 3 | | 1996 | 0 | 4 | 4 | | 1997 | 0 | 2 | 2 | | 1998 | 0 | 5 | 5 | | 1999 | 0 | 3 | 3 | | 2000 | 0 | 4 | 4 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 5 | 5 | | 2003 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2010 | 0 | 3 | 3 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 3 | 3 | | 2013 | 0 | 2 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 3 | 3 | | 2017 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Biotransformation" by people in Profiles.
-
Kandel SE, Han LW, Mao Q, Lampe JN. Digging Deeper into CYP3A Testosterone Metabolism: Kinetic, Regioselectivity, and Stereoselectivity Differences between CYP3A4/5 and CYP3A7. Drug Metab Dispos. 2017 12; 45(12):1266-1275.
-
Kim S, Rossmassler K, Broeckling CD, Galloway S, Prenni J, De Long SK. Impact of inoculum sources on biotransformation of pharmaceuticals and personal care products. Water Res. 2017 11 15; 125:227-236.
-
Rhee MS, Wei L, Sawhney N, Kim YS, Rice JD, Preston JF. Metabolic potential of Bacillus subtilis 168 for the direct conversion of xylans to fermentation products. Appl Microbiol Biotechnol. 2016 Feb; 100(3):1501-1510.
-
Keen OS, Love NG, Aga DS, Linden KG. Biodegradability of iopromide products after UV/H2O2 advanced oxidation. Chemosphere. 2016 Feb; 144:989-94.
-
Zuckerman M, Greller HA, Babu KM. A Review of the Toxicologic Implications of Obesity. J Med Toxicol. 2015 Sep; 11(3):342-54.
-
Rudolph J, Erbse AH, Behlen LS, Copley SD. A radical intermediate in the conversion of pentachlorophenol to tetrachlorohydroquinone by Sphingobium chlorophenolicum. Biochemistry. 2014 Oct 21; 53(41):6539-49.
-
Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics. 2013 Dec; 23(12):721-8.
-
Aquilante CL, Wempe MF, Sidhom MS, Kosmiski LA, Predhomme JA. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. Eur J Clin Pharmacol. 2013 Jul; 69(7):1401-9.
-
Fukuda T, Goebel J, Cox S, Maseck D, Zhang K, Sherbotie JR, Ellis EN, James LP, Ward RM, Vinks AA. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther Drug Monit. 2012 Dec; 34(6):671-9.
-
Keen OS, Baik S, Linden KG, Aga DS, Love NG. Enhanced biodegradation of carbamazepine after UV/H2O2 advanced oxidation. Environ Sci Technol. 2012 Jun 05; 46(11):6222-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|